G lomerular filtration rate (GFR) has long been considered the best overall index of kidney function in health and disease. The rationale is that GFR is a property of the kidney, has a large range, and is affected by physiologic, pharmacologic, and pathologic conditions. Furthermore, GFR decline is associated with many physiologic and clinical consequences and is correlated with decline in other excretory functions, such as tubular reabsorption and secretion, as well as endocrine and metabolic functions. Decreased GFR is one criterion in the definition and staging of acute and chronic kidney diseases, and GFR estimating equations are recommended for routine use for kidney function assessment in clinical practice. 1 For a number of reasons, some have questioned the appropriateness of GFR as the "gold standard" for defining kidney disease and assessing kidney function. [2] [3] [4] While it can be important to question accepted concepts, to date, no alternative measure has been proposed to replace GFR as an index of kidney function or decreased GFR as a criterion for defining kidney disease.
Glomerular filtration cannot be measured directly in humans; thus "true" GFR cannot be known with certainty. However, GFR can be assessed from clearance measurements (measured GFR [mGFR]) or serum levels of endogenous filtration markers (estimated GFR [eGFR]). Urinary inulin clearance, the classic method for measuring GFR described by Smith, 5 is too difficult for clinical practice and research purposes; consequently, alternative filtration markers and clearance methods are used to measure GFR (Table 1 ). In particular, 2 methods that have been used in recent studies are of importance in developing and validating GFR estimating equations. Urinary iothalamate clearance is the basis for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations using creatinine and cystatin C that are recommended by current guidelines. 6, 7 Meanwhile, plasma clearance of iohexol is now being used more widely in research studies, including those to assess the CKD-EPI equations and develop other equations. [8] [9] [10] In this issue of AJKD, Seegmiller and colleagues 11 describe observed differences between the urinary clearances of iothalamate and iohexol. The goals of this editorial are to provide explanations for these observed differences and explore the implications of these differences on the utility of GFR as a gold standard.
Seegmiller and colleagues
11,12 developed a liquid chromatography-tandem mass spectrometry method to enable simultaneous determination of nonradioactive iothalamate and iohexol in serum and urine. They then compared simultaneous urinary clearances of both markers after bolus subcutaneous infusion in 150 patients with a wide range of GFRs. The mean proportional ratio of iohexol to iothalamate clearance was 0.85 (95% confidence interval, 0.83-0.88) across the range of GFRs, indicating that GFR determined using iohexol clearance is lower than that determined using iothalamate clearance. To further explore this finding, Seegmiller et al 11 performed in vitro dialysis experiments using plasma samples from 10 patients, which demonstrated a lower ratio of dialysate to plasma concentration of iohexol than iothalamate, suggesting iohexol is less "filterable" than iothalamate, perhaps because of binding to plasma proteins. The authors concluded that the nonequivalence of iohexol and iothalamate clearances should be taken into account in studies that use these filtration markers to measure GFR.
In principle, explanations for observed differences between urinary clearances of iohexol and iothalamate could include any of the following: slower equilibration of iohexol than iothalamate between subcutaneous tissue and plasma, tubular secretion of iothalamate, and protein binding, tubular reabsorption, or extrarenal elimination of iohexol. A recent systematic review by Soveri and colleagues 13 showed that some but not all prior studies demonstrate that urinary iothalamate clearances overestimate urinary inulin clearance, whereas those of iohexol underestimate it. Of interest, differences between plasma clearance of iohexol and urinary clearance of inulin were smaller, likely due to extrarenal elimination of iohexol.
Strengths of the study by Seegmiller and colleagues 11 are a large study population, rigorous assay methods, and simultaneous measurement of urinary clearances. Expression of the results as clearance ratios eliminates possible errors in the measurement of urine flow rate (eg, due to incomplete bladder emptying) as a cause of the difference between filtration markers. Limitations of the study are the short equilibration period before the clearance In clinical practice, procedures are frequently abbreviated, including shortening the equilibrium period and obtaining fewer urine and blood samples over a shorter interval. measurement, absence of simultaneous measurements of urinary clearance of inulin and plasma clearance of iohexol, and absence of in vivo or in vitro investigations for the cause of lesser filtration of iohexol. Further clarification on these points could be derived from a comprehensive study of urinary and plasma clearance of commonly used exogenous filtration markers compared to urinary inulin clearance. In addition, this would also allow "calibration" among methods, which could be useful for clinical practice and research.
With respect to their implications for the concept of GFR as an index of kidney function, the findings reported in Seegmiller et al 11 do not diminish the pathophysiologic importance of GFR or its role in clinical decision making. As the first step in urine formation, glomerular filtration has a dominant influence in the excretory functions of the kidney, but alterations in other aforementioned kidney functions are also associated with important clinical manifestations. In addition, GFR does not reflect the cause, duration, or likelihood of remission or progression of kidney disease. Furthermore, markers of kidney damage (eg, albuminuria, urine sediment abnormalities, or pathologic or imaging abnormalities) and complications associated with decreased GFR (eg, anemia, hyperparathyroidism, or metabolic acidosis) also provide important diagnostic and prognostic information. Thus, evaluating GFR is essential but not sufficient for the clinical assessment of kidney disease.
The findings of Seegmiller et al have implications for the interpretation of mGFR. Both mGFR and eGFR have error compared to true GFR. Even the classic method of inulin clearance is imprecise, and together, the systematic review by Soveri et al 13 and the new study from Seegmiller and colleagues 11 suggest that clearances of both iothalamate and iohexol are biased compared to true GFR. At the present time, GFR measurement methods vary and are not standardized across referral centers or research studies. The work by Seegmiller et al 11 reinforces the importance of clinicians and investigators appreciating that mGFR results may vary across centers and studies according to methods.
The findings of Seegmiller et al 11 may also have implications for the development and evaluation of estimation equations. Bias and precision of eGFR compared to mGFR may be affected by the GFR measurement method used for developing the estimating equation. The MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI equations were developed using urinary clearance of iothalamate, so direct comparisons between them are unbiased. However, comparisons between these 2 equations and others developed using alternative mGFR methods are subject to bias due to potential differences in the mGFR method, which may account in part for the heterogeneity of findings in past studies evaluating GFR estimating equations. 14 The findings by Seegmiller et al may raise questions about the use of mGFR as a confirmatory test for decreased eGFR. The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for evaluating and managing CKD recommends that clinicians use creatinine-based eGFR (eGFR cr ) as an initial test and either cystatin C-based eGFR (eGFR cr-cys or eGFR cys ) or mGFR as a confirmatory test if a more accurate assessment is required for clinical decision making. 1 The most important causes for inaccuracy in eGFR are a nonsteady state (eg, acute kidney injury), presence of non-GFR determinants of filtration markers (eg, extremes of muscle mass for creatinine or hyperthyroidism for cystatin C), and interference with filtration marker assays (eg, ketoacids for alkalinepicrate assays for creatinine). In our view, mGFR remains helpful in these cases, and differences among mGFR methods highlighted by Seegmiller et al 11 are probably small compared with errors in eGFR.
Finally, the study by Seegmiller et al 11 may have implications for interpretation of studies comparing associations of eGFR and mGFR. Studies that compare associations of eGFR and mGFR with markers of kidney damage or with complications or outcomes of kidney disease (eg, kidney failure or mortality) do not evaluate the accuracy of eGFR compared to mGFR. Instead, they are useful for evaluating GFR versus non-GFR pathways to explain associations with eGFR. In these studies, imprecision in mGFR may obscure true differences between GFR versus non-GFR associations, especially if imprecision in mGFR is large in comparison to the imprecision in other measures of disease. 15 This is a particular problem in studies of kidney disease progression, in which the imprecision in mGFR is large in comparison to its rate of decline. 16, 17 Overall, the study by Seegmiller and colleagues 11 provides further information on GFR measurement methods. In our view, the differences between iothalamate and iohexol clearances probably reflect small and opposite biases compared to urinary inulin clearance, so that true GFR is likely in between them (Table 1 ). These differences are unlikely to be of clinical importance at GFRs less than w90 mL/min/ 1.73 m be biased compared to true GFR. Standardization and calibration across methods could be helpful in clinical and research studies, including the development of more accurate eGFR equations.
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